Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

192

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

November 30, 2024

Study Completion Date

October 1, 2030

Conditions
Metastatic Prostate Cancer
Trial Locations (16)

AB15 6RE

Aberdeen Royal Infirmary, Aberdeen

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

CF15 7QZ

Velindre University NHS Trust, Cardiff

DN2 5LT

Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster

ME7 5NY

Medway NHS Foundation Trust, Gillingham

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

CM20 1QX

The Princess Alexandra Hospital NHS Trust, London

E1 1FR

Barts Health NHS Trust, Royal London Hospital, London

KT2 7QB

Kingston Hospital NHS Foundation Trust, London

NW3 2QG

Royal Free London NHS Foundation Trust, London

SE1 9RT

Guy's and St Thomas's NHS Foundation Trust, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

W1T 4TJ

University College London Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Epic Sciences

INDUSTRY

lead

University College, London

OTHER

NCT04067713 - Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter